Focuses on three key therapeutic areas
Strategic focus involves the proactive pursuit of First-in-Class and Best-in-Class small molecule therapeutics.
A First-in-class liposomal drug that effectively regulates the immune system's balance for prophylaxis against acute Graft-versus-Host Disease (aGvHD).
Many blood disorders, such as leukemia, require allogeneic hematopoietic stem cell transplantation (AHSCT) as a vital treatment option. However, graft-versus-host disease (GvHD), where immune cells from the donor attack the recipient's organs, remains a major and potentially fatal complication of AHSCT1.
BPC2001 (originally named RGI-2001) is a new chemical entity (NCE) with liposomal formulation.
Its primary mechanism involves inducing an increase in regulatory T cells (Treg), thereby initiating specific immune tolerance. This action serves to alleviate rejection-related immune responses while preserving the donor immune cells' anti-cancer effect (graft-versus-leukemia, GvL) 2, ultimately achieving the prevention of acute Graft-versus-Host Disease (aGvHD).
BPC2001 has the potential to improve the success rate of bone marrow transplantation by preventing acute graft-versus-host disease (aGvHD), offering meaningful benefits to a broad population of patients with hematologic disorders.
BPC2002 is the First-in-Class new drug designed to treat psoriasis by regulating the immune balance mechanism. It aims to offer more effective and innovative treatment options.
Psoriasis is a chronic, immune-mediated skin disease characterized by redness and silvery-white scales. It commonly affects the scalp, elbows, knees, and various other areas of the body. In some cases, it may also be associated with arthritis. Although current treatments, including topical medications and biologics, can effectively alleviate symptoms, some patients either do not respond adequately or are unable to use these treatments over the long term. This highlights a significant unmet medical need for psoriasis therapies that offer improved efficacy, stability, reduced side effects, and better long-term management.
BPC2002 is a new derivative of BPC2001. Utilizing innovative dosage forms, BPC2002 modulates the immune system by promoting a Th2 response while inhibiting a Th1 response. Additionally, it reduces IL-17-related inflammatory activity, effectively treating psoriasis.
Through innovative dosage forms, BPC2002 is anticipated to restore immune balance and enhance the treatment of patients with psoriasis.
BPC2003 is an innovative drug that employs a novel mechanism of immune modulation to reduce the risk of kidney transplant rejection.
Kidney transplantation is the primary treatment for end-stage renal disease, effectively restoring kidney function and enhancing patients' quality of life. However, rejection reactions are common following surgery and can lead to graft failure. While immunosuppressive drugs are available, they present challenges, including side effects and inconsistent long-term efficacy. Therefore, effective rejection control remains a critical unmet medical need.
BPC2003, a new derivative of BPC2001, is designed to inhibit transplant rejection by inducing the proliferation of regulatory T cells (Tregs) and initiating antigen-specific immune tolerance.
BPC2003 is expected to enhancethe anti-rejection response by modulating immune homeostasis, thereby preserving renal function and improving overall treatment outcomes in transplant patients.